AR and prostate carcinoma: Similarly, it has been reported that a NDI derivative synergistically interacted with Enzalutamide, an inhibitor of the androgen receptor (AR) signaling used in first-line therapies for metastatic castration-resistant prostate cancer, as a consequence of its ability to stabilize the G4 within the AR gene promoter and to remarkable reduced AR protein amounts as well as to significantly affect the expression levels of genes involved in the activation of AR program via feedback mechanisms [74].